Where can I find 688331.SS's financial statements?

RemeGen Co. Ltd. Class A (688331.SS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for 688331.SS?

RemeGen Co. Ltd. Class A (688331.SS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does 688331.SS update its statements?

RemeGen Co. Ltd. Class A files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

688331.SS

RemeGen Co. Ltd. Class A

SHH·Medical, Pharmaceuticals · Healthcare

¥125.18¥1.72−1.36%

Market cap¥69.28B·Market closed·Jul 23 3:29 AM UTC

CNY · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Trend
Revenue	¥1.42B	¥772.11M−45.8%	¥1.08B+40.3%	¥1.72B+58.5%	¥3.25B+89.3%
Cost of revenue	¥67.16M	¥272.05M+305.1%	¥257.27M−5.4%	¥346.72M+34.8%	¥631.30M+82.1%
Gross profit	¥1.36B	¥500.06M−63.1%	¥825.68M+65.1%	¥1.37B+65.9%	¥2.62B+91.1%
Research & development	¥710.97M+52.6%	¥982.08M+38.1%	¥1.60B+62.5%	¥1.56B−2.5%	¥1.10B−29.0%
General & administrative	¥219.84M+1.0%	¥266.31M+21.1%	¥304.23M+14.2%	¥316.71M+4.1%	—
Selling & marketing	¥262.97M+987.5%	¥440.70M+67.6%	¥775.19M+75.9%	¥948.76M+22.4%	—
SG&A (combined)	¥482.81M+99.7%	¥707.01M+46.4%	¥1.08B+52.7%	¥1.27B+17.2%	¥1.37B+8.5%
Other operating expenses	¥121.00K+157.4%	−¥193.78M−160,251.1%	−¥348.23M−79.7%	¥4.11M+101.2%	¥10.81M+162.9%
Total operating expenses	¥1.19B+68.7%	¥1.50B+25.2%	¥2.33B+55.6%	¥2.83B+21.4%	¥2.49B−12.0%
Operating income	¥162.84M+123.0%	−¥995.25M−711.2%	−¥1.50B−50.9%	−¥1.46B+3.1%	¥130.20M+108.9%
Interest income	¥43.35M+2,519.2%	¥61.54M+42.0%	¥28.14M−54.3%	¥10.24M−63.6%	¥5.02M−51.0%
Interest expense	¥5.32M−81.8%	¥6.76M+26.9%	¥23.09M+241.7%	¥72.38M+213.5%	¥70.35M−2.8%
Other income / (expense), net	¥113.42M+1,051.5%	−¥3.58M−103.2%	−¥9.70M−170.6%	−¥12.71M−31.0%	¥580.20M+4,666.6%
Income before tax	¥276.26M+139.6%	−¥998.83M−461.6%	−¥1.51B−51.3%	−¥1.47B+2.8%	¥710.40M+148.4%
Income tax expense	—	—	—	—	¥748.69K	—
Net income	¥276.26M+139.6%	−¥998.83M−461.6%	−¥1.51B−51.3%	−¥1.47B+2.8%	¥709.65M+148.3%

EPS (basic)	¥0.57+133.3%	−¥1.88−429.8%	−¥2.80−48.9%	−¥2.73+2.5%	¥1.29+147.3%
EPS (diluted)	¥0.57+133.3%	−¥1.88−429.8%	−¥2.80−48.9%	−¥2.73+2.5%	¥1.29+147.3%
Weighted avg shares (basic)	487,444,155	531,292,778	539,724,705	537,861,098	549,242,868
Weighted avg shares (diluted)	487,443,301	531,292,778	539,724,705	537,861,098	549,242,868

Depreciation & amortization	¥66.24M+32.8%	¥124.03M+87.3%	¥176.12M+42.0%	¥231.01M+31.2%	¥320.34M+38.7%
EBITDA	¥347.82M+156.2%	−¥868.04M−349.6%	−¥1.31B−51.1%	−¥1.16B+11.2%	¥1.10B+194.5%

Frequently Asked Questions About 688331.SS

Where can I find 688331.SS's financial statements?: RemeGen Co. Ltd. Class A (688331.SS)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for 688331.SS?: RemeGen Co. Ltd. Class A (688331.SS) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does 688331.SS update its statements?: RemeGen Co. Ltd. Class A files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

¥1.42B

¥772.11M−45.8%

¥1.08B+40.3%

¥1.72B+58.5%

¥3.25B+89.3%

Cost of revenue

¥67.16M

¥272.05M+305.1%

¥257.27M−5.4%

¥346.72M+34.8%

¥631.30M+82.1%

Gross profit

¥1.36B

¥500.06M−63.1%

¥825.68M+65.1%

¥1.37B+65.9%

¥2.62B+91.1%

Research & development

¥710.97M+52.6%

¥982.08M+38.1%

¥1.60B+62.5%

¥1.56B−2.5%

¥1.10B−29.0%

General & administrative

¥219.84M+1.0%

¥266.31M+21.1%

¥304.23M+14.2%

¥316.71M+4.1%

—

Selling & marketing

¥262.97M+987.5%

¥440.70M+67.6%

¥775.19M+75.9%

¥948.76M+22.4%

—

SG&A (combined)

¥482.81M+99.7%

¥707.01M+46.4%

¥1.08B+52.7%

¥1.27B+17.2%

¥1.37B+8.5%

Other operating expenses

¥121.00K+157.4%

−¥193.78M−160,251.1%

−¥348.23M−79.7%

¥4.11M+101.2%

¥10.81M+162.9%

Total operating expenses

¥1.19B+68.7%

¥1.50B+25.2%

¥2.33B+55.6%

¥2.83B+21.4%

¥2.49B−12.0%

Operating income

¥162.84M+123.0%

−¥995.25M−711.2%

−¥1.50B−50.9%

−¥1.46B+3.1%

¥130.20M+108.9%

Interest income

¥43.35M+2,519.2%

¥61.54M+42.0%

¥28.14M−54.3%

¥10.24M−63.6%

¥5.02M−51.0%

Interest expense

¥5.32M−81.8%

¥6.76M+26.9%

¥23.09M+241.7%

¥72.38M+213.5%

¥70.35M−2.8%

Other income / (expense), net

¥113.42M+1,051.5%

−¥3.58M−103.2%

−¥9.70M−170.6%

−¥12.71M−31.0%

¥580.20M+4,666.6%

Income before tax

¥276.26M+139.6%

−¥998.83M−461.6%

−¥1.51B−51.3%

−¥1.47B+2.8%

¥710.40M+148.4%

Income tax expense

—

¥748.69K

—

Net income

¥276.26M+139.6%

−¥998.83M−461.6%

−¥1.51B−51.3%

−¥1.47B+2.8%

¥709.65M+148.3%

EPS (basic)

¥0.57+133.3%

−¥1.88−429.8%

−¥2.80−48.9%

−¥2.73+2.5%

¥1.29+147.3%

EPS (diluted)

¥0.57+133.3%

−¥1.88−429.8%

−¥2.80−48.9%

−¥2.73+2.5%

¥1.29+147.3%

Weighted avg shares (basic)

487,444,155

531,292,778

539,724,705

537,861,098

549,242,868

Weighted avg shares (diluted)

487,443,301

531,292,778

539,724,705

537,861,098

549,242,868

Depreciation & amortization

¥66.24M+32.8%

¥124.03M+87.3%

¥176.12M+42.0%

¥231.01M+31.2%

¥320.34M+38.7%

EBITDA

¥347.82M+156.2%

−¥868.04M−349.6%

−¥1.31B−51.1%

−¥1.16B+11.2%

¥1.10B+194.5%